Drug intelligence / Profile preview

VMTE

Development stage: Preclinical
Modality: Cell Therapies, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intraperitoneal

Overview

VMTE (virus-modified tumor cell extracts) is a cell-based immunotherapy derived from allogeneic ovarian cancer cell lines (OV2774 and CaOV3) that have been modified with the influenza virus A/PR8/34. Administered intraperitoneally, VMTE is designed to induce regional cellular immunity and enhance the oncolytic activity of effector cells against tumor cells in patients with advanced ovarian cancer. Its therapeutic effect can be further potentiated by co-administration with interleukin-2 (IL-2).

Other names: virus-modified tumor cell extracts

Beyond the preview

Go deeper on VMTE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VMTE.

Explore the full profile